Corporate Profile


We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.

By leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Royalty bearing collaborations with Sino Biopharm and Hepalys Pharma, Inc.

Innovative clinical programs: NATiV3, LEGEND.

Pre-clinical pipeline in oncology and fibrosis.

State-of-the-art R&D capabilities inherited from Abbott, Solvay, Fournier.

Financial Information


Inventiva is not holding any liquidity or investments at SVB, therefore our liquidity and activities are not impacted by the recent events.

Upcoming Events

2023 Annual Results Press Release

27th March 2024

Publication of the cash position and revenues as of March 31, 2024

21st May 2024

Euronext Share Information

€4.205 +10.66%

Last update: Mar 19, 2024 at 09:55 CET


Open: €4.1
Previous close: €3.8

Day High: €4.3
Day Low: €4.01

Presentations


6th March 2024
TD Cowen 44th Annual Health Care Conference
15th November 2023
Stifel Healthcare Conference

Governance


Inventiva was co-founded by Frédéric Cren, Chairman, CEO and Co-Founder and Pierre Broqua, Chief Scientific Officer in Dijon in 2012.

Both have strong expertise within the areas of research, development and strategy and held senior research and executive positions at both Fournier and Solvay prior to founding Inventiva.

Investor Contacts


Inventiva
50 rue de Dijon
21121 Daix, France
Email: finance@inventivapharma.com
Tel: +33 (0)3 80 44 75 00

Patti Bank
Managing Director
ICR Westwicke
Patti.Bank@westwicke.com
D 415-513-1284
San Francisco, CA
www.westwicke.com